Investors
Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.


Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.

Investors

4:00 PM EDT • Oct 27, 2020
QTNT
4.57USD
-0.22%
Contact

Peter Buhler, Chief Financial Officer 

IR@quotientbd.com

3 Months
6 Months
12 Months
Quotient Ltd
$

Events & presentations

Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
Quotient Limited to Publish Quarterly Investor Presentation

Press releases

Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody Test
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
Financials & filings

Get up-to-date information about our Company’s financials.

Corporate governance

Retrieve corporate policy documents, committee charters, and more. 

Stock information

Follow our latest stock quote and historical information.

Our reagents by Quotient
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.